Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q3 2023 Results Conference Call November 8, 2023 4:30 PM ET

Company Participants

Sherry Aulin - Chief Financial Officer

Ian Mortimer - President and Chief Executive Officer

Chris Kenney - Chief Medical Officer

Chris Von Seggern - Chief Commercial Officer

Conference Call Participants

Paul Matteis - Stifel

Brian Abrahams - RBC Capital Markets

Tessa Romero - JPMorgan

Andrew Tsai - Jefferies

Paul Choi - Goldman Sachs

Joseph Thome - TD Cowen

Danielle Brill - Raymond James

Tim Lugo - William Blair

Operator

Hello, thank you for standing by. And welcome to Xenon Pharmaceuticals Incorporated Third Quarter 2023 Earnings Conference Call. I would now like to turn the call over to Sherry Aulin, our CFO. You may now begin the conference.

Sherry Aulin

Thank you. Good afternoon, everyone. Thank you for joining us on our call and webcast to discuss Xenon's third quarter 2023 financial and operating results. Joining me are Ian Mortimer, Xenon's President and Chief Executive Officer; Dr. Chris Kenney, Xenon's Chief Medical Officer; and Dr. Chris Von Seggern, Xenon's Chief Commercial Officer. Ian will open today's call with a summary of our progress, Kenney will provide an overview of our ongoing XEN1101 clinical program and Chris Von Seggern will summarize key findings from our market research around the potential of 1101 in major depressive disorder or MDD treatment landscape. I will summarize our financial results, progress within our partnered programs and anticipated company milestone events before opening the call to your questions. Please be advised that during this call, we will make a number of statements that are forward-looking, including statements regarding the timing of and potential results from our and our collaborators’ clinical trials; the potential efficacy, safety profile, future development plans, addressable market, regulatory success and commercial potential of our and our partners' product candidates; the efficacy of our clinical trial designs, our ability to successfully develop and achieve milestones in our XEN1101 and other development programs; the timing and results of our interactions with regulators, our ability to successfully develop and obtain regulatory approval of XEN1101 and our other product candidates; anticipated enrollment in our clinical trials and the timing thereof; and our expectation that we will have sufficient cash to fund operations into 2026. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond our control, including the risks and uncertainties described from time to time in our SEC filings. Our results may differ materially from those projected on today's call. We undertake no obligation to publicly update any forward-looking statements. Today's press release summarizing Xenon's third quarter financial results and the accompanying report on Form 10-Q will be made available under the Investors section of our Web site at www.xenon-pharma.com and filed with the SEC and on SEDAR.